Valuation dashboard for SELLAS Life Sciences Group, Inc. (SLS) with P/E N/A, P/B 15.27, EV/EBITDA -91.42 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At $10.38 (closing price, October 28, 2026), SLS has negative trailing earnings (P/E not meaningful) and an ROE of -35.91%. Market capitalisation stands at $2.1B.
Balance sheet quality for SLS: current ratio of 10.7. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 15.27 |
| EV / EBITDA | -91.42 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $0.63 |
| vs Current Price | -94.0% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| SLS | SELLAS Life Sciences Group, Inc. | $2.1B | 15.27 | -35.9% | |
| INCY | Incyte Corporation | $23.7B | 14.89 | 3.59 | 29.7% |
| IDYA | IDEAYA Biosciences, Inc. | $3.3B | 2.61 | -16.5% | |
| IMNM | Immunome, Inc. | $2.2B | 4.22 | -50.6% | |
| NRIX | Nurix Therapeutics, Inc. | $3.0B | 11.80 | 3.17 | 49.3% |
Price
| Price | $10.38 (closing price, October 28, 2026) |
| Market Cap | $2.1B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -35.91% |
| Return on Invested Capital | -25.45% |
| Return on Assets | -22.33% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: INCY · IDYA · IMNM · NRIX
Explore sector: Healthcare · Biotechnology
More sections of SLS: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks